LakeShore Biopharma Announces US$15 Million Private Placement Financing

Rhea-AI Summary

LakeShore Biopharma (NASDAQ:LSB), a global biopharmaceutical company focused on vaccines and therapeutic biologics, has announced a US$15 million private placement financing agreement with an institutional investor.

The deal includes the issuance of 16,987,542 ordinary shares at US$0.883 per share, along with an equal number of warrants. Each warrant allows the purchase of one ordinary share at US$1.079 during a 36-month period. The private placement, exempt from registration under Regulation S, is expected to close upon meeting customary conditions.

Positive

• Secured US$15 million in additional funding through private placement
• Warrants provide potential for additional future funding at US$1.079 per share
• Share price of US$0.883 represents confidence in company value

Negative

• Significant dilution for existing shareholders with issuance of 16.99M new shares
• Additional potential dilution from 16.99M warrants if exercised
• Financing through private placement might indicate limited traditional funding options

Insights

Biotech Investment Analyst

LakeShore Biopharma secured $15M financing through private placement, providing capital but at below-market terms with 20% dilution potential.

LakeShore Biopharma has secured $15 million in financing through a private placement with an institutional investor. The structure involves selling 16,987,542 ordinary shares at $0.883 per share, alongside an equal number of warrants exercisable at $1.079 per share over the next 36 months.

This financing appears to be a double-edged sword for the company. On the positive side, it strengthens LakeShore's cash position, providing crucial capital for its biopharmaceutical operations focused on vaccines and therapeutics for infectious diseases and cancer. However, the share price of $0.883 suggests the company is raising capital at potentially unfavorable terms, which often indicates financial pressure.

The warrant component is particularly significant. If all warrants are exercised, the company would receive an additional $18.3 million, but this would come with approximately 20% dilution for existing shareholders. The exercise price of $1.079 represents only a 22% premium to the current placement price, which is relatively modest for a biotech company.

This Regulation S offering targeting non-U.S. investors suggests the company is diversifying its funding sources, but also potentially indicates limitations in accessing U.S. capital markets. For a Nasdaq-listed company, raising capital through this structure might signal challenges in securing more conventional financing. The timing and structure of this deal merit attention as they may reflect both the company's immediate capital needs and the market's assessment of its risk profile.

BEIJING, July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into a share and warrant purchase agreement (the "Purchase Agreement") with an institutional investor for the issuance and sale of 16,987,542 ordinary shares of the Company, par value US$0.0002 per share, at US$0.883 per share, and 16,987,542 warrants, each entitling the institutional investor to purchase one ordinary share at an exercise price of US$1.079 at any time and from time to time during a 36-month period, in a private placement of US$15 million exempt from registration pursuant to Regulation S under the Securities Act of 1933, as amended. The closing of the private placement is expected to take place as soon as possible upon agreement by the parties to the Purchase Agreement, subject to customary conditions precedent stipulated thereunder.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation, or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Safe Harbor Statement

This press release contains "forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of the Company, the development progress of all product candidates, the progress and results of all clinical trials, the Company's ability to source and retain talent, and the cash position of the Company. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target," or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance.

The Company cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the Company's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. However, while the Company may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of the Company as of any date subsequent to the date of this press release. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-us15-million-private-placement-financing-302500058.html

SOURCE LakeShore Biopharma Co., Ltd.

FAQ

What is the size of LakeShore Biopharma's (LSB) private placement financing?

LakeShore Biopharma secured a US$15 million private placement financing through the issuance of shares and warrants to an institutional investor.

How many shares is LSB issuing in the private placement?

LSB is issuing 16,987,542 ordinary shares at US$0.883 per share, along with an equal number of warrants.

What are the terms of LSB's warrant offering?

Each warrant allows the purchase of one ordinary share at US$1.079 during a 36-month exercise period.

How will the private placement affect LSB shareholders?

The private placement will result in dilution for existing shareholders due to the issuance of 16.99M new shares, with potential additional dilution if warrants are exercised.

When will LSB's private placement close?

The private placement is expected to close as soon as possible upon agreement by the parties, subject to customary conditions precedent.